News

Created by Atlas Venture and Caribou Biosciences, together with leading scientists who have pioneered and shaped the field of CRISPR biology, Intellia leverages exclusive access to one of

The collaboration will focus on new therapeutic approaches for the treatment of various acute neurological conditions resulting from neurovascular instability. This discovery collaboration brings together Edge’s scientific expertise

"We are proud and hopeful to play a role to develop a treatment that could potentially reduce the rate of prosthesis abandonment for those who have so honorably

This invention is for a nanotechnology process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid nanosomes for use in combination therapy by means of Aphios’ SuperFluids technology

The territory covers China including Mainland China, Taiwan, Hong Kong and Macau as well as other countries, including Thailand, Brazil and Russia. 3SBio president and CEO Dr Jing

Harvoni is a combination of the NS5A inhibitor ledipasvir (LDV) and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) and is indicated to treat adults with chronic hepatitis C

The US Food and Drug Administration (FDA) approval of Trumenba is based on the demonstration of immune response, as measured by serum bactericidal activity against four serogroup B

The approval is based on positive data from the Phase III VIVID-DME and VISTA-DME trials and one open label single arm safety trial in Japanese patients (VIVID-Japan). During

Both the firms have not been disclosed financial details of the agreement. Aspen has agreed to specific annual commercial goals for Brinavess. Cardiome chief commercial officer Karim Lalji